A federal court this week reversed a number of Patent Trial and Appeal Board rulings which invalidated patents held by Becton Dickinson & Co. (NYSE:BDX) subsidiary C.R. Bard in an ongoing patent spat with AngioDynamics (NSDQ:ANGO) .
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,